Scientists at The Pirbright Institute have engineered synthetic antibody molecules that can be administered to poultry to reduce the symptoms of influenza, as well as decreasing the amount of influenza virus they shed into the environment. These results suggest that there is potential for their use as immunotherapy treatments to reduce the burden of influenza in poultry.
The Pirbright Institute is joining in the global battle to help control COVID-19 by using its unique expertise and facilities to support the development of vaccines to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the current pandemic.
Scientists at The Pirbright Institute have shown that two new potential vaccines against Nipah virus developed by the University of Parma generate a strong immune response in pigs. These promising results suggest the vaccines could protect pigs against Nipah virus infection, which can cause respiratory problems and fatal encephalitis in pigs and humans.